EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Aravive's enterprise value is $-3.16 Mil.
Aravive's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $7.00 Mil. Therefore, Aravive's EV-to-Revenue for today is -0.45.
The historical rank and industry rank for Aravive's EV-to-Revenue or its related term are showing as below:
ARAV'
s EV-to-Revenue Range Over the Past 10 Years
Min: -9.17 Med: 2.04 Max: 54.65
Current: -0.45
During the past 11 years, the highest EV-to-Revenue of Aravive was 54.65. The lowest was -9.17. And the median was 2.04.
ARAV's EV-to-Revenue is not ranked
in the Biotechnology industry.
Industry Median: 7.775
vs ARAV: -0.45
As of today (2024-09-20), Aravive's stock price is $0.0401.
Aravive's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.09. Therefore, Aravive's PS Ratio for today is 0.43.
Aravive EV-to-Revenue Historical Data
The historical data trend for Aravive's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Aravive's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aravive's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aravive's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Aravive's EV-to-Revenue falls into.
Aravive's current Enterprise Value is $-3.16 Mil.
Aravive's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aravive's share price for today is $0.0401.
Aravive's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.09.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aravive EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Aravive's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ARAV has been successfully added to your 